26
FEB
2019

NW Bio Hires David Innes As Vice President, Investor Relations

Posted By :
Comments : Off
31 Years Managing Portfolios At Several Major Wall Street Firms, With Emphasis On Biotech BETHESDA, MD, February 26, 2019 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has hired David Innes as Vice President, Investor Relations. Innes comes to NW Bio with over 31 years of managing portfolios at major...
Read More
08
FEB
2019

NW Bio Releases Voting Results From Annual Shareholders’ Meeting

Posted By :
Comments : Off
BETHESDA, Md., February 8, 2019 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today released the final voting results from the Annual Shareholder Meeting held on February 2, 2019. Votes were cast by 460,778,696 (88.7%) of the total 519,729,780 shares that were issued and outstanding on the record date of December 13, 2018, and as such...
Read More
25
JAN
2019

Presentation By NWBio CEO At The Phacilitate Leaders World 2019 Conference

Posted By :
Comments : Off
Focus on Complexity and Variability of Solid Tumors, and How DCVax®-L Addresses Them BETHESDA, Md., January 25, 2019 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its CEO, Linda Powers, presented at the Phacilitate Leaders World 2019 Conference in Miami, Florida. The slide deck from this presentation can be...
Read More
14
DEC
2018

NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds

Posted By :
Comments : Off
BETHESDA, Md., December 14, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that the package transaction involving the Company’s UK property, which the Company announced earlier this week, closed today in the UK. The closing included the transaction elements previously announced: The funding of approximately...
Read More
11
DEC
2018

NW Bio Announces Non-Dilutive Funding of Approximately $47.3 Million Through UK Property Transaction

Posted By :
Comments : Off
BETHESDA, Md., December 11, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has entered into agreements with a large multi-national corporation for a package transaction involving the Company’s property located near Cambridge, UK.  Pursuant to these agreements, The Company will sell most of its UK...
Read More